CCR5 inhibitors in HIV-1 therapy (Q38089881)

28 August 2017

title

CCR5 inhibitors in HIV-1 therapy (English)

1 reference

28 August 2017

Patrick Dorr

1

1 reference

28 August 2017

Manos Perros

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

Expert Opinion on Drug Discovery

28 August 2017

published in

1 reference

28 August 2017

volume

3

1 reference

28 August 2017

issue

11

1 reference

28 August 2017

page(s)

1345-1361

1 reference

An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Toxicity of antiretroviral therapy and implications for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

The prevalence of antiretroviral drug resistance in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Prospects of HIV-1 entry inhibitors as novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

The entry of entry inhibitors: a fusion of science and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Resistance to enfuvirtide, the first HIV fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

The many roles of chemokines and chemokine receptors in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Target validation of G-protein coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Identification of a major co-receptor for primary isolates of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Genotypic and phenotypic characterization of HIV-1 patients with primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Lack of alternative coreceptor use by pediatric HIV-1 R5 isolates for infection of primary cord or adult peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Dancing to the tune of chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

The chemokine receptor, CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

The CCR5- 32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

A genetic basis for human susceptibility to West Nile virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

CCR5: no longer a "good for nothing" gene--chemokine control of West Nile virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

HIV and the chemokine system: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

CCR5 blockade modulates inflammation and alloimmunity in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Molecular modeling and site-directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Targeting chemokine receptors in HIV: a status report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.11.1345

10.1517/17460441.3.11.1345

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference